Progress of immune checkpoint inhibitors in extranodal NK/T cell lymphoma

VernacularTitle:免疫检查点抑制剂在结外NK/T细胞淋巴瘤中的研究进展
Author: Huanan LI ¹ ; Zunmin ZHU ; Xiaoli YUAN
Author Information

1. 河南大学人民医院　河南省人民医院血液内科　河南省人民医院血液病研究所，郑州　450003
Keywords: Lymphoma, extranodal NK-T-cell; Programmed-death receptor 1; Programmed-death receptor ligand 1; Mechanisms of drug resistance; Combination therapy
From: Journal of Leukemia & Lymphoma 2023;32(11):701-704
CountryChina
Language:Chinese
Abstract: Extranodal NK/T cell lymphoma (ENKTCL) is a group of highly aggressive non-Hodgkin lymphoma associated with epstein-barr virus infection. Asparaginase-based chemoradiotherapy regimens are not effective in advanced patients. In recent years, anti-programmed-death receptor 1 (PD-1)/programmed-death receptor ligand 1 (PD-L1) immunotherapy has developed rapidly, which can effectively improve the prognosis of ENKTCL patients. But some patients with ENKTCL still have low response rate. This article reviews the mechanisms of resistance to anti-PD1/PD-L1 therapy and other immune targets in ENKTCL recently to change the traditional treatment mode of ENKTCL through the combination of different targeted drugs.